Roche Holding AG
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Thomas Schinecker
- Full Time Employees
- 103,249
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- Grenzacherstrasse 124 Basel BS Switzerland 4070
- IPO Date
- Aug 20, 2003
- Website
- roche.com
- Similar Companies
- Business
- Roche Holding AG, headquartered in Basel, Switzerland and founded in 1896, operates as one of the world's largest biotechnology companies and the global leader in in-vitro diagnostics; it develops and markets innovative medicines and diagnostic products across oncology, immunology, infectious diseases, ophthalmology, neuroscience, hematology, respiratory diseases, cardiovascular, renal and metabolic disorders, rare diseases, and women's health, with key pharmaceutical brands including Avastin, MabThera/Rituxan, Herceptin, Perjeta, Tecentriq, Hemlibra, Ocrevus, and Vabysmo; its diagnostics portfolio encompasses in-vitro diagnostics, point-of-care testing such as the recently FDA-cleared CLIA-waived test for Bordetella infections including whooping cough, continuous glucose monitoring systems, cell analysis, gene expression, genome sequencing, and nucleic acid purification technologies; the company serves customers worldwide through operations in more than 130 countries, with significant presence via wholly-owned Genentech in the United States and majority stake in Japan's Chugai Pharmaceutical. Roche maintains two primary segments, Pharmaceuticals and Diagnostics, targeting healthcare providers, researchers, and patients with personalized healthcare solutions that integrate data insights from clinical practice. Recent developments include a definitive merger agreement in September 2025 to acquire 89bio for up to $3.5 billion to bolster its cardiovascular, renal, and metabolic portfolio with pegozafermin for moderate to severe MASH; a $50 billion investment commitment over five years announced in April 2025 to expand U.S. R&D and manufacturing in states including Indiana, Pennsylvania, Massachusetts, and California, creating over 12,000 jobs; a $550 million expansion of its Indianapolis diagnostics site for continuous glucose monitoring by 2030; prior acquisitions such as Carmot Therapeutics in 2024, Televant Holdings for $7.1 billion in 2023, and partnerships like those with Innovent Biologics and Poseida Therapeutics; and 53 new collaboration agreements in 2024 alongside ongoing M&A firepower of about $10 billion annually.
Company News
Roche Expands Obesity Pipeline With Rona's RNAi Candidate
Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics
Roche Reports Positive Phase III Data on Eye Drug, FDA Accepts BLA
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines
Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
Gen Announces Appointment of Talbott Roche to Board of Directors
Roche Gets FDA Approval for Another Label Expansion of Tecentriq
FDA approves Roche’s Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer
BAYRY vs. RHHBY: Which Stock Should Value Investors Buy Now?
Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market?
Roche Holding AG (RHHBY) Discusses Pharma Strategy, R&D Excellence, AI in Drug Development, and Pipeline Updates Across Key Therapeutic Areas Transcript
Merck, Daiichi Withdraw FDA Filing for Lung Cancer Therapy
Roche outlines plans to move towards autonomous AI labs
NTHM's Index Rebalance Puts Thematic Rotation to Work
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?
Roche signs drug-discovery deal with Atavistik Bio worth up to $2 billion
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
Roche Drops as Phase 3 Kidney Signal Needs Two-Year Proof
Roche: Latest Obesity Data Suggests Pharma Is In Line To Become Global GLP-1 Player
Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease